AXOGEN INC (AXGN) Stock Fundamental Analysis
NASDAQ:AXGN - Nasdaq - US05463X1063 - Common Stock - Currency: USD
Taking everything into account, AXGN scores 5 out of 10 in our fundamental rating. AXGN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AXGN get a neutral evaluation. Nothing too spectacular is happening here. AXGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AXGN was profitable.
In the past year AXGN had a positive cash flow from operations.
AXGN had negative earnings in each of the past 5 years.
In the past 5 years AXGN reported 4 times negative operating cash flow.
1.2 Ratios
AXGN's Return On Assets of -2.27% is fine compared to the rest of the industry. AXGN outperforms 67.91% of its industry peers.
The Return On Equity of AXGN (-4.15%) is better than 70.05% of its industry peers.
AXGN has a Return On Invested Capital of 0.75%. This is in the better half of the industry: AXGN outperforms 65.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -4.15% | ||
| ROIC | 0.75% |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AXGN's Operating Margin of 0.84% is fine compared to the rest of the industry. AXGN outperforms 64.17% of its industry peers.
Looking at the Gross Margin, with a value of 74.27%, AXGN belongs to the top of the industry, outperforming 86.10% of the companies in the same industry.
In the last couple of years the Gross Margin of AXGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.84% | ||
| PM (TTM) | N/A | ||
| GM | 74.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AXGN is destroying value.
The number of shares outstanding for AXGN has been increased compared to 1 year ago.
Compared to 5 years ago, AXGN has more shares outstanding
AXGN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.03 indicates that AXGN is not in any danger for bankruptcy at the moment.
AXGN has a Altman-Z score of 4.03. This is in the better half of the industry: AXGN outperforms 75.40% of its industry peers.
The Debt to FCF ratio of AXGN is 13.85, which is on the high side as it means it would take AXGN, 13.85 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AXGN (13.85) is better than 72.73% of its industry peers.
AXGN has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AXGN (0.43) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 13.85 | ||
| Altman-Z | 4.03 |
ROIC/WACC0.08
WACC9.15%
2.3 Liquidity
A Current Ratio of 4.14 indicates that AXGN has no problem at all paying its short term obligations.
AXGN's Current ratio of 4.14 is fine compared to the rest of the industry. AXGN outperforms 68.45% of its industry peers.
A Quick Ratio of 2.67 indicates that AXGN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.67, AXGN is in the better half of the industry, outperforming 62.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.14 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 500.00% over the past year.
The Revenue has grown by 17.17% in the past year. This is quite good.
The Revenue has been growing by 11.92% on average over the past years. This is quite good.
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%
3.2 Future
Based on estimates for the next years, AXGN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.38% on average per year.
The Revenue is expected to grow by 16.23% on average over the next years. This is quite good.
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y87.49%
EPS Next 5Y50.38%
Revenue Next Year16.08%
Revenue Next 2Y16.17%
Revenue Next 3Y14.14%
Revenue Next 5Y16.23%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 65.71, which means the current valuation is very expensive for AXGN.
66.31% of the companies in the same industry are more expensive than AXGN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.86. AXGN is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 32.55, the valuation of AXGN can be described as expensive.
AXGN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AXGN is cheaper than 70.59% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AXGN to the average of the S&P500 Index (34.94), we can say AXGN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.71 | ||
| Fwd PE | 32.55 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AXGN indicates a somewhat cheap valuation: AXGN is cheaper than 62.57% of the companies listed in the same industry.
AXGN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AXGN is cheaper than 67.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 207.26 | ||
| EV/EBITDA | 77.12 |
4.3 Compensation for Growth
AXGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AXGN's earnings are expected to grow with 87.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.04
PEG (5Y)N/A
EPS Next 2Y93.05%
EPS Next 3Y87.49%
5. Dividend
5.1 Amount
AXGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AXGN (8/21/2025, 3:13:37 PM)
15.77
+0.21 (+1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners86.63%
Inst Owner Change1.77%
Ins Owners0.92%
Ins Owner Change-0.03%
Market Cap718.17M
Analysts84.29
Price Target24.74 (56.88%)
Short Float %9.45%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-68.39%
Min EPS beat(2)-222.55%
Max EPS beat(2)85.77%
EPS beat(4)3
Avg EPS beat(4)275.79%
Min EPS beat(4)-222.55%
Max EPS beat(4)1125.49%
EPS beat(8)7
Avg EPS beat(8)185.94%
EPS beat(12)11
Avg EPS beat(12)146.94%
EPS beat(16)14
Avg EPS beat(16)116.93%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)5.47%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)5.47%
Revenue beat(8)5
Avg Revenue beat(8)1.38%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)7
Avg Revenue beat(16)-0.53%
PT rev (1m)0%
PT rev (3m)-7.18%
EPS NQ rev (1m)4.99%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.34%
Revenue NQ rev (1m)0.89%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.71 | ||
| Fwd PE | 32.55 | ||
| P/S | 3.53 | ||
| P/FCF | 207.26 | ||
| P/OCF | 99.93 | ||
| P/B | 6.4 | ||
| P/tB | 6.76 | ||
| EV/EBITDA | 77.12 |
EPS(TTM)0.24
EY1.52%
EPS(NY)0.48
Fwd EY3.07%
FCF(TTM)0.08
FCFY0.48%
OCF(TTM)0.16
OCFY1%
SpS4.46
BVpS2.47
TBVpS2.33
PEG (NY)1.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -4.15% | ||
| ROCE | 0.95% | ||
| ROIC | 0.75% | ||
| ROICexc | 0.9% | ||
| ROICexgc | 0.94% | ||
| OM | 0.84% | ||
| PM (TTM) | N/A | ||
| GM | 74.27% | ||
| FCFM | 1.7% |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 13.85 | ||
| Debt/EBITDA | 5.16 | ||
| Cap/Depr | 49.09% | ||
| Cap/Sales | 1.83% | ||
| Interest Coverage | 0.24 | ||
| Cash Conversion | 77.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.14 | ||
| Quick Ratio | 2.67 | ||
| Altman-Z | 4.03 |
F-Score6
WACC9.15%
ROIC/WACC0.08
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y63.46%
EPS Next 2Y93.05%
EPS Next 3Y87.49%
EPS Next 5Y50.38%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%
Revenue Next Year16.08%
Revenue Next 2Y16.17%
Revenue Next 3Y14.14%
Revenue Next 5Y16.23%
EBIT growth 1Y114.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1384.37%
EBIT Next 3Y205.47%
EBIT Next 5YN/A
FCF growth 1Y112.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y211.25%
OCF growth 3YN/A
OCF growth 5YN/A